The psychopharmacology algorithm project at the harvard south shore program: An update on posttraumatic stress disorder

Harvard Review of Psychiatry

Volumn 19, Issue 5, 2011, Pages 240-258

  Bajor, Laura A ^a   Ticlea, Ana Nectara ^a   Osser, David N ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Algorithms; Posttraumatic stress disorder; Psychopharmacology; Stress disorders

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; BROFAROMINE; CITALOPRAM; DESIPRAMINE; DOXAZOSIN; DOXEPIN; ESZOPICLONE; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; MIRTAZAPINE; NEFAZODONE; OLANZAPINE; PAROXETINE; PHENELZINE; PRAZOSIN; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERAZOSIN; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZOLPIDEM;

ADJUVANT THERAPY; ALGORITHM; ANOREXIA; ANTICHOLINERGIC SYNDROME; BEDTIME DOSAGE; BIPOLAR DISORDER; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; CONSTIPATION; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISSOCIATIVE DISORDER; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULARY; DRUG INTERACTION; DRUG MEGADOSE; DRUG PROGRAM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY EYE; EFFECT SIZE; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; EXPERIMENT; FATIGUE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE QUALITY; HEART DISEASE; HUMAN; INSOMNIA; INTERMETHOD COMPARISON; LIVER TOXICITY; LOW DRUG DOSE; MAJOR DEPRESSION; METABOLIC DISORDER; MONOTHERAPY; NIGHTMARE; NOSE CONGESTION; POSTTRAUMATIC STRESS DISORDER; PREGNANCY; PRIAPISM; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEIZURE SUSCEPTIBILITY; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP; SMOKING; SOMNOLENCE; STANDING; SUBSTANCE ABUSE; SYMPTOMATOLOGY; SYNCOPE; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL HALLUCINATION; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ALGORITHMS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; HUMANS; MIANSERIN; PRAZOSIN; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS; STRESS DISORDERS, POST-TRAUMATIC; TRAZODONE; TRIAZOLES;

EID: 80052877236     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.3109/10673229.2011.614483     Document Type: Review

References (146)

1. Germain A, Buysse DJ, Nofzinger E. Sleep-specific mechanisms underlying posttraumatic stress disorder: integra-tive review and neurobiological hypotheses. Sleep Med Rev 2008;12:185-95. (Pubitemid 351657734)
2. Rasmusson AM, Vythilingam M, Morgan CA 3rd. The neu-roendocrinology of posttraumatic stress disorder: new directions. CNS Spectr 2003;8:651-6, 665-7.
3. Wang Z, Neylan TC, Mueller SG, et al. Magnetic resonance imaging of hippocampal subfields in posttraumatic stress disorder. Arch Gen Psychiatry 2010;67:296-303.
4. Osser DN, Renner JA, Bayog R. Algorithms for the pharma-cotherapy of anxiety disorders in patients with chemical abuse and dependence. Psychiatr Ann 1999;29:285-301.
5. Davidson J, Bernik M, Connor KM, Friedman MJ, Jobson KO, Yoshiharo K. A new treatment algorithm for posttraumatic stress disorder. Psychiatr Ann 2005;35:887-98. (Pubitemid 41640830)
6. Foa EB, Keane TM, Friedman MJ, Cohen JA. Effective treatments for PTSD: practice guidelines from the International Society for Traumatic Stress Studies. 2nd ed. New York: Guil-ford, 2008.
7. National Collaborating Centre for Mental Health. Post-traumatic stress disorder: the management of PTSD in adults and children in primary and secondary care. London; Leicester, UK: Gaskell and the British Psychological Society, 2005.
8. Bisson JI. Post-traumatic stress disorder. Clin Evid (Online). 2007 Aug 1; 2007. pii:1005.
9. Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2005;(2):CD003388.
10. Benedek DM, Friedman MJ, Zatzick D, Ursano RJ. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Arlington, VA: American Psychiatric Publishing, 2009
11. Committee on Treatment of Posttraumatic Stress Disorder, Institute of Medicine. Treatment of posttraumatic stress disorder: an assessment of the evidence. Washington, DC: National Academies, 2008.
12. Hamoda HM, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on psychotic depression. Harv Rev Psychiatry 2008;16: 235-47.
13. Ansari A, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on bipolar depression. Harv Rev Psychiatry 2010;18:36-55.
14. Osser DN, Dunlop LR. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on generalized social anxiety disorder. Psychopharm Rev 2010;45:91-8.
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: American Psychiatric Press, 2000.
16. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluox-etine in posttraumatic stress disorder. J Clin Psychiatry 1994;55:517-22.
17. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 2007;68:711-20. (Pubitemid 46841854)
18. Strawn JR, Geracioti TD Jr. Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depress Anxiety 2008;25:260-71. (Pubitemid 351499905)
19. Chilcoat HD, Breslau N. Posttraumatic stress disorder and drug disorders: testing causal pathways. Arch Gen Psychiatry 1998;55:913-7. (Pubitemid 28465781)
20. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996;275:761-7. (Pubitemid 26087197)
21. Otto MW, Perlman CA, Wernicke R, Reese HE, Bauer MS, Pollack MH. Posttraumatic stress disorder in patients with bipolar disorder: a review of prevalence, correlates, and treatment strategies. Bipolar Disord 2004;6:470-9. (Pubitemid 39562414)
22. Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol 2007;10:253-61.
23. Breslau N, Davis GC, Peterson EL, Schultz LR. A second look at comorbidity in victims of trauma: the posttraumatic stress disorder-major depression connection. Biol Psychiatry 2000;48:902-9.
24. Gill J, Vythilingam M, Page GG. Low cortisol, high DHEA, and high levels of stimulated TNF-alpha, and IL-6 in women with PTSD. J Trauma Stress 2008;21:530-9.
25. Rasmusson AM, Wu R, Paliwal P, Anderson GM, Krishnan-Sarin S. A decrease in the plasma DHEA to cortisol ratio during smoking abstinence may predict relapse: a preliminary study. Psychopharmacology (Berl) 2006;186:473-80. (Pubitemid 43804803)
26. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Far-fel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001;58:485-92. (Pubitemid 32411330)
27. Brady KT, Clary CM. Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline. Compr Psychiatry 2003;44:360-9. (Pubitemid 37151811)
28. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001;158:1982-8. (Pubitemid 33104102)
29. Lewis CC, Simons AD, Nguyen LJ. Impact of childhood trauma on treatment outcome in the treatment for adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry 2010;49:132-40.
30. Brand BL, Classen CC, McNary SW, Zaveri P. A review of dissociative disorders treatment studies. J Nerv Ment Dis 2009;197:646-54.
31. Marshall RD, Lewis-Fernandez R, Blanco C, et al. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety 2007;24:77-84. (Pubitemid 46516663)
32. Steiner H, Carrion V, Plattner B, Koopman C. Dissociative symptoms in posttraumatic stress disorder: diagnosis and treatment. Child Adolesc Psychiatr Clin N Am 2003;12:231-49, viii. (Pubitemid 36437834)
33. Menon SJ. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet 2008;277:1-13. (Pubitemid 350160081)
34. Kirby AC, Hertzberg BP, Collie CF, et al. Smoking in help-seeking veterans with PTSD returning from Afghanistan and Iraq. Addict Behav 2008;33:1448-53.
35. Cook J, Jakupcak M, Rosenheck R, Fontana A, McFall M. Influenceof PTSD symptom clusters onsmoking status among help-seeking Iraq and Afghanistan veterans. Nicotine Tob Res 2009;11:1189-95.
36. Hertzberg MA, Moore SD, Feldman ME, Beckham JC. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychopharmacol 2001;21:94-8. (Pubitemid 32096757)
37. Spoormaker VI, Montgomery P. Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature? Sleep Med Rev 2008;12:169-84.
38. Belleville G, Guay S, Marchand A. Impact of sleep disturbances on PTSD symptoms and perceived health. J Nerv Ment Dis 2009;197:126-32.
39. Thompson CE, Taylor FB, McFall ME, Barnes RF, Raskind MA. Nonnightmare distressed awakenings in veterans with posttraumatic stress disorder: response to prazosin. J Trauma Stress 2008;21:417-20.
40. Neylan TC, Marmar CR, Metzler TJ, et al. Sleep disturbances in the Vietnam generation: findings from a nationally representative sample of male Vietnam veterans. Am J Psychiatry 1998;155:929-33. (Pubitemid 28307605)
41. Mellman TA, Knorr BR, Pigeon WR, Leiter JC, Akay M. Heart rate variability during sleep and the early development of posttraumatic stress disorder. Biol Psychiatry 2004;55: 953-6. (Pubitemid 38526309)
42. Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003;160:371-3. (Pubitemid 41110467)
43. Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007;61:928-34. (Pubitemid 46505008)
44. Lamarche LJ, De Koninck J. Sleep disturbance in adults with posttraumatic stress disorder: a review. J Clin Psychiatry 2007;68:1257-70. (Pubitemid 47395629)
45. Kobayashi I, Boarts JM, Delahanty DL. Polysomnographically measured sleep abnormalities in PTSD: a meta-analytic review. Psychophysiology 2007;44:660-9. (Pubitemid 46905333)
46. Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008;63:629-32. (Pubitemid 351273194)
47. Byers MG, Allison KM, Wendel CS, Lee JK. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol 2010;30:225-9.
48. Nuzhat SS, Osser DN. Chest pain in a young patient treated with prazosin for PTSD. Am J Psychiatry 2009;166: 618-9.
49. Contopoulos-Ioannidis DC, Gilbody SM, Trikalinos TA, Churchill R, Wahlbeck K, Ioannidis J. Comparison of large versus smaller trials for mental-health interventions. Am J Psychiatry 2005;162:578-84. (Pubitemid 40343926)
50. Troxel WM, Buysse DJ, Matthews KA, et al. Sleep symptoms predict the development of the metabolic syndrome. Sleep 2010;33:1633-40.
51. Chung. Effect of terazosin on posttraumatic nightmares. Poster (No. 356) presented at the annual meeting of the American Psychiatric Association, San Diego, CA, May 2007.
52. De Jong J, Wauben P, Huijbrechts I, Oolders H, Haffmans J. Doxazosin treatment for posttraumatic stress disorder. J Clin Psychopharmacol 2010;30:84-5.
53. Hertzberg MA, Feldman ME, Beckham JC, Davidson JR. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol 1996;16:294-8. (Pubitemid 26254880)
54. Leshner HI, Bagdhoyan HA, Bennett SJ, Caples SM, DeRubeis RJ, Glynn RJ. NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements 2005;22(2):1-30.
55. Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry 2001;34:128-31. (Pubitemid 32701761)
56. Sadock BJ, Sadock VA. Trazodone. In: Kaplan and Sadock's pocket handbook of psychiatric drug treatment. New York: Lippincott Williams & Wilkins, 2001:237-40.
57. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009;14:536-46.
58. Walsh JK. Subjective hypnotic efficacy of trazodone and zolpi-dem in DSM III-R primary insomnia. Hum Psychopharmacol 1998;13:191-8. (Pubitemid 28216251)
59. Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med 2004;5:15-20. (Pubitemid 38145707)
60. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994;151:1069-72. (Pubitemid 24208646)
61. Davidson J, Kudler H, Smith R, et al. Treatment of posttrau-matic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990;47:259-66. (Pubitemid 20086679)
62. Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL Jr. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991;179:366-70.
63. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008;69:1557-64.
64. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22:511-5.
65. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990;51:236-8. (Pubitemid 20209219)
66. Baker DG, Nievergelt CM, Risbrough VB. Post-traumatic stress disorder: emerging concepts of pharmacotherapy. Expert Opin Emerg Drugs 2009;14:251-72.
67. Pollack MH, Hoge EA, Worthington JJ. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:892-7.
68. Wine JN, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharma-cother 2009;43:707-13.
69. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;70:1041-50.
70. Williams SG, Alinejad NA, Williams JA, Cruess DF. Statistically significant increase in weight caused by low-dose queti-apine. Pharmacotherapy 2010;30:1011-5.
71. Hamner MB, Canive J, Robert S, Calais LA, Villarreal G, Durkalski V. Quetiapine monotherapy in chronic posttrau-matic stress disorder: a randomized, double-blind, placebo-controlled trial. Paper presented at the annual meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
72. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorber-baum JP. Quetiapine treatment in patients with posttrau-matic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 2003;23:15-20. (Pubitemid 36164420)
73. Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont) 2009;6:16-8.
74. Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttrau-matic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr 2009;14:25-31.
75. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000;283:1837-44. (Pubitemid 30207620)
76. Tucker P, Potter-Kimball R, Wyatt DB, et al. Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull 2003;37:135-49.
77. Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC. Fluox-etine versus placebo in posttraumatic stress disorder. J Clin Psychiatry 2002;63:199-206. (Pubitemid 34407078)
78. Martenyi F, Soldatenkova V. Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: analysis of the veteran group of a placebo-controlled, randomized clinical trial. Eur Neuropsychophar-macol 2006;16:340-9. (Pubitemid 43898670)
79. Martenyi F, Brown EB, Caldwell CD. Failed efficacy of fluoxe-tine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. J Clin Psychophar-macol 2007;27:166-70. (Pubitemid 46594933)
80. Seedat S, Stein DJ, Emsley RA. Open trial of citalopram in adults with post-traumatic stress disorder. Int J Neuropsy-chopharmacol 2000;3:135-40. (Pubitemid 30429357)
81. English BA, Jewell M, Jewell G, Ambrose S, Davis LL. Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trial. J Clin Psychopharmacol 2006;26:84-8. (Pubitemid 43167097)
82. Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry 2006;67: 1522-6. (Pubitemid 44787433)
83. Canive JM, Clark RD, Calais LA, Qualls C, Tuason VB. Bupro-pion treatment in veterans with posttraumatic stress disorder: an open study. J Clin Psychopharmacol 1998;18:379-83. (Pubitemid 28462627)
84. Becker ME, Hertzberg MA, Moore SD, Dennis MF, Bukenya DS, Beckham JC. A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol 2007;27:193-7. (Pubitemid 46594938)
85. Bahk WM, Pae CU, Tsoh J, et al. Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. Hum Psychopharmacol 2002;17:341-4. (Pubitemid 35189816)
86. Chung MY, Min KH, Jun YJ, Kim SS, Kim WC, Jun EM. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol 2004;19:489-94. (Pubitemid 39378271)
87. Davidson JR, Weisler RH, Butterfield MI, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 2003;53:188-91. (Pubitemid 36126484)
88. Kim W, Pae CU, Chae JH, Jun TY, Bahk WM. The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24-week continuation therapy. Psychiatry Clin Neurosci 2005;59:743-7. (Pubitemid 43151671)
89. Preskorn SH. Outpatient management of depression: a guide for the practitioner. 3rd ed. West Islip, NY: Professional Communications, 2009.
90. David D, Kutcher GS, Jackson EI, Mellman TA. Psychotic symptoms in combat-related posttraumatic stress disorder. J Clin Psychiatry 1999;60:29-32. (Pubitemid 29069882)
91. Moskowitz A, ed. Psychosis, trauma, and dissociation. Oxford: Wiley & Sons, 2009.
92. Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychophar-macol 2003;18:1-8. (Pubitemid 36127054)
93. Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH. Placebo-controlled trial of risperi-done augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry 2008;69:520-5. (Pubitemid 351792325)
94. Pivac N, Kozaric-Kovacic D, Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychophar-macology (Berl) 2004;175:451-6. (Pubitemid 39362043)
95. Robert S, Hamner MB, Durkalski VL, Brown MW, Ulmer HG. An open-label assessment of aripiprazole in the treatment of PTSD. Psychopharmacol Bull 2009;42:69-80.
96. Hamner MB, Canive J, Robert S, Calais LA, Villarreal G, Durkalski V. Quetiapine monotherapy in chronic posttrau-matic stress disorder: a randomized, double-blind, placebo-controlled trial. Paper presented at the annual meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
97. Southwick SM. Noradrenergic alterartions in posttraumatic stress disorder. Ann N Y Acad Sci 1997;821:125-41. (Pubitemid 27343016)
98. Murphy SE, Yiend J, Lester KJ, Cowen PJ, Harmer CJ. Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers. Int J Neuropsychopharmacol 2009;12:169-79.
99. Reist C, Kauffmann CD, Haier RJ, et al. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 1989;146:513-6. (Pubitemid 19099304)
100. Davidson J, Baldwin D, Stein DJ, et al. Treatment of post-traumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006;63:1158-65. (Pubitemid 44498394)
101. Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ. Venlafaxine extended release in posttraumatic stress disorder: a sertraline-and placebo-controlled study. J Clin Psychopharmacol 2006;26:259-67. (Pubitemid 43804617)
102. Rothbaum BO, Davidson JR, Stein DJ, et al. A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo. J Clin Psychiatry 2008;69:1529-39.
103. Stein DJ, Pedersen R. Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis. Int J Neuropsychopharmacol 2009;12:23-31.
104. Gelenberg AJ. Nefazedone hepatotoxicity: black box warning. Biol Ther Psychiatry 2002;25:2.
105. Davis LL, Nugent AL, Murray J, Kramer GL, Petty F. Nefa-zodone treatment for chronic posttraumatic stress disorder: an open trial. J Clin Psychopharmacol 2000;20:159-64. (Pubitemid 30202357)
106. Garfield DA, Fichtner CG, Leveroni C, Mahableshwarkar A. Open trial of nefazodone for combat veterans with posttrau-matic stress disorder. J Trauma Stress 2001;14:453-60. (Pubitemid 32778065)
107. Davis LL, Jewell ME, Ambrose S, et al. A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. J Clin Psychopharmacol 2004;24:291-7. (Pubitemid 38658037)
108. McRae AL, Brady KT, Mellman TA, et al. Comparison of ne-fazodone and sertraline for the treatment of posttraumatic stress disorder. Depress Anxiety 2004;19:190-6. (Pubitemid 38685537)
109. Hidalgo R, Hertzberg MA, Mellman T, et al. Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol 1999;14:61-8. (Pubitemid 29149863)
110. Hertzberg MA, Feldman ME, Beckham JC, Moore SD, Davidson JR. Open trial of nefazodone for combat-related posttrau-matic stress disorder. J Clin Psychiatry 1998;59:460-4. (Pubitemid 28447199)
111. Hertzberg MA, Feldman ME, Beckham JC, Moore SD, Davidson JR. Three-to four-year follow-up to an open trial of nefa-zodone for combat-related posttraumatic stress disorder. Ann Clin Psychiatry 2002;14:215-21. (Pubitemid 36231914)
112. Zisook S, Chentsova-Dutton YE, Smith-Vaniz A, et al. Nefa-zodone in patients with treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 2000;61:203-8. (Pubitemid 30214517)
113. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991;52:361-4.
114. Davis LL, Davidson JR, Ward LC, Bartolucci A, Bowden CL, Petty F. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychophar-macol 2008;28:84-8.
115. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999;45:1226-9. (Pubitemid 29236566)
116. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:201-6. (Pubitemid 46362640)
117. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol 2007;27:677-81. (Pubitemid 351339456)
118. Kinrys G, Wygant L, Pardo T, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 2006;67:211-4. (Pubitemid 43357466)
119. Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psy-chopharmacology (Berl) 2006;184:21-5. (Pubitemid 43005753)
120. Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007;27:85-8. (Pubitemid 46105772)
121. Pae CU, Lim HK, Peindl K, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol 2008;23:1-8. (Pubitemid 350294864)
122. Monnelly EP, Ciraulo DA, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003;23:193-6. (Pubitemid 36368797)
123. Krystal J, Rosenheck R, Cramer J. Adjunctive risperi-done treatment for antidepressant-resistant symptoms of chronic military service-related PTSD. JAMA 2011;306: 493-502.
124. Ahearn EP, Mussey M, Johnson C, Krohn A, Krahn D. Que-tiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. Int Clin Psychopharma-col 2006;21:29-33. (Pubitemid 43175120)
125. Villarreal G, Calais LA, Canive JM, Lundy SL, Pickard J, Toney G. Prospective study to evaluate the efficacy of arip-iprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Psychopharma-col Bull 2007;40:6-18.
126. Mello MF, Costa MC, Schoedl AF, Fiks JP. Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. Rev Bras Psiquiatr 2008;30:358-61.
127. Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psy-chopharmacol 2001;16:197-203. (Pubitemid 32612517)
128. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159:1777-9.
129. Siddiqui Z, Marcil WA, Bhatia SC, Ramaswamy S, Petty F. Ziprasidone therapy for post-traumatic stress disorder. J Psychiatry Neurosci 2005;30:430-1. (Pubitemid 41812490)
130. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35.
131. Pies R. Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety? Psychiatry (Edgmont) 2009;6:29-37.
132. Kinzie JD, Leung P. Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis 1989;177:546-50. (Pubitemid 19233931)
133. Ziegenhorn AA, Roepke S, Schommer NC, et al. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychophar-macol 2009;29:170-3.
134. Neylan TC, Lenoci M, Samuelson KW, et al. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 2006;163:2186-8. (Pubitemid 46114243)
135. Davis LL, Ward C, Rasmusson A, Newell JM, Frazier E, Southwick SM. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull 2008;41:8-18.
136. Pitman RK, Sanders KM, Zusman RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002;51:189-92. (Pubitemid 34127909)
137. Vaiva G, Ducrocq F, Jezequel K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003;54:947-9. (Pubitemid 37311359)
138. Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacother-apy to prevent PTSD: results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 2007;20:923-32.
139. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysio-logic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res 2008;42:503-6. (Pubitemid 351240920)
140. Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res 1988;24:149-55.
141. Baker DG, Diamond BI, Gillette G, et al. A double-blind, randomized, placebo-controlled, multi-center study of bro-faromine in the treatment of post-traumatic stress disorder. Psychopharmacology (Berl) 1995;122:386-9. (Pubitemid 26011419)
142. Katz RJ, Lott MH, Arbus P, et al. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety 1994;1:169-74.
143. American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and posttrau-matic stress disorder. Arlington, VA: APA, 2004.
144. Foa EB, Davidson JR, Frances A. The expert consensus guidelines: treatment of posttraumatic stress disorder. J Clin Psychiatry 1999;60 (suppl 16).
145. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006; 51(8 suppl 2):9S-91S.
146. United States Department of Veterans Affairs; United States Department of Defense. Clinical practice guideline for management of post-traumatic stress. Washington, DC: Veterans Health Administration, DoD, 2010.